MedTrace Logo

Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens

NCT05871489 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2024-12-05

No results posted yet for this study

Summary

This is a multisite prospective cohort study of patients with multidrug- or rifampin-resistant tuberculosis who are treated with an all-oral shortened regimen under routine program conditions in one of three countries (Peru, Lesotho, Kazakhstan).

Conditions

  • Tuberculosis, Multidrug-Resistant
  • HIV

Interventions

DRUG

Bdq, Lzd, Lfx, Dlm, Cfz (9-12 months)

Bdq, Lzd, Lfx, Dlm, Cfz for nine months, with extension to 12 months as needed

DRUG

Bdq, Lzd, Lfx, Cfz, Cs (9-12 months)

Bdq, Lzd, Lfx, Cfz, Cs for nine months, with extension to 12 months as needed

DRUG

Bdq, Lzd, Lfx, Z, Dlm (9-12 months)

Bdq, Lzd, Lfx, Z, Dlm for nine months, with extension to 12 months as needed

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Partners in Health

    collaborator OTHER

  • Socios En Salud Sucursal, Peru

    collaborator OTHER

  • Harvard Medical School (HMS and HSDM)

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2025-12-30
Completion
2025-12-31

Countries

  • Kazakhstan
  • Lesotho
  • Peru

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05871489 on ClinicalTrials.gov